WO2024039333A1 - Pharmaceutical compositions comprising ivacaftor - Google Patents

Pharmaceutical compositions comprising ivacaftor Download PDF

Info

Publication number
WO2024039333A1
WO2024039333A1 PCT/TR2023/050789 TR2023050789W WO2024039333A1 WO 2024039333 A1 WO2024039333 A1 WO 2024039333A1 TR 2023050789 W TR2023050789 W TR 2023050789W WO 2024039333 A1 WO2024039333 A1 WO 2024039333A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
weight
ivacaftor
composition according
polyvinyl
Prior art date
Application number
PCT/TR2023/050789
Other languages
French (fr)
Inventor
Busra ARI
Ozlem GULTEKIN INCE
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/012995 external-priority patent/TR2022012995A1/en
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2024039333A1 publication Critical patent/WO2024039333A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers.
  • the pharmaceutical composition is obtained by using an effective process.
  • Ivacaftor is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and is indicated for the treatment of cystic fibrosis in patients who have a G55ID mutation in the CFTR gene.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • Ivacaftor is a white powder that is practically insoluble in water ( ⁇ 0.05 microgram/mL) and its having an empirical formula of C24H28N2O3 and a molecular weight of 392.499 g/moL.
  • Ivacaftor was approved by FDA in 2012 and developed by VERTEX® pharmaceuticals in amorphous solid dispersion tablets form under the trade name Kalydeco for the treatment of cystic fibrosis. Ivacaftor is currently marketed as tablets in strength of 75 mg and 150 mg and oral granules in strength of 25 mg, 50 mg and 75 mg per packet under the trade name Kalydeco and is indicated for the treatment of cystic fibrosis in patients age 6 years and older who have a G55ID mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • Ivacaftor has low water solubility, very lipophilic and bioavailability of Ivacaftor is significantly enhanced when co-administered with food.
  • Kalydeco is administered orally and it is recommended with a fatty meal to aid in its stomach absorption to improve its bioavailability and overall exposure.
  • Ivacaftor molecule has been disclosed in W02006002421 patent.
  • W02007079139 disclosed amorphous solid dispersion with Ivacaftor and polymer.
  • the amount of Ivacaftor in the solid dispersion is 50% and the amount of polymer is 50%.
  • WO2010019239 patent discloses that this amorphous solid dispersion was improved reducing the quantity of polymer until about 20% and increasing the quantity of ivacaftor until 80% in the solid dispersion.
  • W02007134279 patent discloses a pharmaceutical composition comprising Ivacaftor, PEG 400 and PVP K30.
  • a pharmaceutical composition comprising Ivacaftor that is stable, having a good content uniformity and exhibits excellent dissolution profile and high bioavailability.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a solid dispersion of Ivacaftor or pharmaceutically acceptable salt thereof and method of manufacturing.
  • the main object of the present invention is to provide a pharmaceutical composition comprising Ivacaftor having excellent high bioavailability, high solubility which is obtained by using effective and reproducible manufacturing method.
  • Ivacaftor refers to Ivacaftor in the form of free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or in amorphous form or mixture thereof.
  • Ivacaftor is practically insoluble in water and it shows poor bioavailability after oral administration.
  • the pharmaceutical composition comprises a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers and wherein the solid dispersion is prepared by hot-melt extrusion.
  • the pharmaceutical composition contains a solid dispersion comprising Ivacaftor.
  • the active ingredient is dispersed in a matrix containing polymers, wherein the solid dispersion is prepared by hot-melt extrusion.
  • solid dispersion as used herein relates to an active ingredient moleculary dissolved in the solid excipient matrix (solid solution).
  • Hot-melt extrusion is a manufacturing process where polymeric materials are heated above their glass-transition temperature and mixed with active ingredient, in order to disperse the active ingredient molecularly into the polymer.
  • heating temperatures are used at zones during the hot melt extrusion.
  • the temperature is chosen according to the properties of the polymers and Ivacaftor.
  • composition of high bioavailability, high solubility and showing improved dissolution rate could be obtained that the presence of at least two polymers in a solid dispersion of Ivacaftor wherein obtained by hot-melt extrusion.
  • the amount of Ivacaftor is between 15.0% and 55.0%, preferably between 25.0% and 40.0% by weight of the total composition
  • Suitable polymers are selected from a group comprising hydroxypropyl methyl cellulose acetate succinate, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, homopolymers and copolymers of polyalkylene oxides, polyethylene glycol and polypropylene glycol, homopolymers and copolymers of N-vinyl lactams, N-vinylpyrrolidone, polyvinylpyrrolidone (PVP), Polyvinylpyrrolidone/vinylacetate (PVP/VA), N-vinylcaprolactam, homopolymers and copolymers of acrylic acid and its derivatives, homopolymers and copolymers of methacrylic acid and its derivatives, methylmethacrylate, methylcellulose, ethylcellulose,
  • graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol was selected as one of the polymers in the hot melt extrusion. It is used to enhance the solubility of poorly water-soluble active ingredients by solid dispersion.
  • the glass transition temperature for graft copolymer of polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol (Soluplus®) is 70 °C: this low glass transition temperature makes (Soluplus®) a good candidate for active ingredients.
  • the polymers are graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus®) and hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
  • the ratio of weight of hydroxypropyl methyl cellulose acetate succinate to the graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol is in the range of between 0.30 and 0.60, preferably 0.38 and 0.50. This ratio provides an improved solubility and dissolution profile; thus its bioequivalence is high.
  • the pharmaceutical composition comprises at least one pharmaceutically excipient selected from fillers, disintegrants, lubricants, glidants, binders or mixtures thereof.
  • Suitable fillers are selected from the group comprising lactose, lactose monohydrate, spray- dried lactose monohydrate, anhydrous lactose, microcrystalline cellulose, pregelatinized starch, mannitol, corn starch, maltodextrin, dextrin, dextrose, erytritol, fructose, maltose, sucrose, xylitol, dicalcium phosphate, hydroxypropyl betadex, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, ethylcellulose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sugar sphericals,
  • a preferred filler to be used is microcrystalline cellulose or lactose or mixtures thereof.
  • the total amount of filler is between 30.0% and 90%, between 55.0% and 70.0 by weight of the total composition.
  • Suitable binders are selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, microcrystalline cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyvinyl alcohol, pregelatinized starch, glucose, natural gums, sucrose, sodium alginate, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • Suitable disintegrants are selected from the group comprising calcium carboxymethyl cellulose, crospovidone, cross-linked carboxymethyl cellulose sodium (croscarmellose sodium), starch, sodium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacryline potassium, sodium alginate, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate or mixtures thereof.
  • the disintegrant is cross-linked carboxymethyl cellulose sodium (croscarmellose sodium).
  • the disintegrant has an amount of at most %5 by weight of the total composition.
  • Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, paraffin and mixtures thereof.
  • the lubricant can be magnesium stearate.
  • the amount of lubricant is between 0.10% and 5.00%, preferably between 0.25% and 2.50%, more preferably between 0.50% and 1 .50% by weight of the total composition.
  • a preferred surfactant to be used according to the present invention is sodium lauryl sulfate, polysorbate 80, poloxamer, most preferably sodium lauryl sulfate.
  • the surfactant is sodium lauryl sulfate.
  • the amount of total surfactant is between 0.05% and 1.50%, preferably between 0.10% and 1 .00% by weight of the total composition.
  • Suitable glidants are selected from a group comprising colloidal silicon dioxide, talc, aluminum silicate or mixtures thereof.
  • the glidant is colloidal silicon dioxide.
  • the amount of glidant is between 0.10% and 5.00%, preferably between 0.25% and 2.50%, more preferably between 0.50% and 1 .50% by weight of the total composition.
  • the pharmaceutical composition comprises Ivacaftor as a active agent, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus®) and hydroxypropyl methyl cellulose acetate succinate (HPMCAS) as polymers, croscarmellose sodium as disintegrant, sodium lauryl sulfate as surfactant, colloidal silicon dioxide as glidant, magnesium stearate as lubricant.
  • the composition comprises, a) 15.0-55.0% by weight Ivacaftor b) 0.50-5.00% by weight HPMCAS c) 3.00-9.00% by weight are graft copolymer of polyvinyl caprolactam, polyvinyl acetate, polyethylene glycol (Soluplus®) d) 1 .00-5.00% by weight croscarmellose sodium e) 20.0-40.0% by weight microcrsytalline cellulose f) 20.0-50.0% by weight lactose g) 0.10-5.00% by weight colloidal silicon dioxide h) 0.05-1 .50% by weight sodium lauryl sulfate i) 0.10-5.00% by weight magnesium stearate
  • the pharmaceutical composition of the invention can be processed into a tablet, capsule form, granules, powders, pellet or unit dose packets.
  • the pharmaceutical composition is especially in the tablet form.
  • a process for preparing a composition comprising a solid dispersion of Ivacaftor is prepared by hot-melt extrusion: of Extrudate: a) Mixing Ivacaftor, graft copolymer of polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol (Soluplus®), HPMCAS and sodium lauryl sulfate b) Melting this mixture in a hot melt extruder for molecular dispersion of Ivacaftor in the polymer to form extrude of Tablet c) Pulverising and sieving the extrudate d) Mixing the extrudate powder, croscarmellose sodium, sodium lauryl sulfate, lactose e) Sieving colloidal silicon dioxide, microcrystalline cellulose and adding to the mixture f) Adding magnesium stearate to the mixture and mixing g) Compressing the mixture into tablets
  • Soluplus graft copolymer of polyvinyl caprolactam, -polyvinyl acetate, -polyethylene glycol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a solid pharmaceutical composition comprising a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers. The pharmaceutical composition is obtained by using an effective process.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING IVACAFTOR
Field of the Invention
The present invention relates to a solid pharmaceutical composition comprising a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers. The pharmaceutical composition is obtained by using an effective process.
Background of the Invention
Ivacaftor is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and is indicated for the treatment of cystic fibrosis in patients who have a G55ID mutation in the CFTR gene.
Ivacaftor is a white powder that is practically insoluble in water (< 0.05 microgram/mL) and its having an empirical formula of C24H28N2O3 and a molecular weight of 392.499 g/moL. Ivacaftor chemically known as N-(2,4-di-tert-butyl-5-hydroxyphenyl)-l,4-dihydro-4- oxoquinoline-3-carboxamide and its chemical structure is shown in the Formula I.
Figure imgf000002_0001
Formula I
Ivacaftor was approved by FDA in 2012 and developed by VERTEX® pharmaceuticals in amorphous solid dispersion tablets form under the trade name Kalydeco for the treatment of cystic fibrosis. Ivacaftor is currently marketed as tablets in strength of 75 mg and 150 mg and oral granules in strength of 25 mg, 50 mg and 75 mg per packet under the trade name Kalydeco and is indicated for the treatment of cystic fibrosis in patients age 6 years and older who have a G55ID mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene.
Ivacaftor has low water solubility, very lipophilic and bioavailability of Ivacaftor is significantly enhanced when co-administered with food. Kalydeco is administered orally and it is recommended with a fatty meal to aid in its stomach absorption to improve its bioavailability and overall exposure.
Ivacaftor molecule has been disclosed in W02006002421 patent. W02007079139 disclosed amorphous solid dispersion with Ivacaftor and polymer. In this patent, the amount of Ivacaftor in the solid dispersion is 50% and the amount of polymer is 50%.
WO2010019239 patent discloses that this amorphous solid dispersion was improved reducing the quantity of polymer until about 20% and increasing the quantity of ivacaftor until 80% in the solid dispersion.
W02007134279 patent discloses a pharmaceutical composition comprising Ivacaftor, PEG 400 and PVP K30.
Accordingly, there is a need for stable, bioavailable and high solubility pharmaceutical compositions of Ivacaftor useful for treating patients suffering from cystic fibrosis.
Hence, it would be desirable to have a pharmaceutical composition comprising Ivacaftor that is stable, having a good content uniformity and exhibits excellent dissolution profile and high bioavailability.
Detailed Description of the Invention
The present invention relates to a pharmaceutical composition comprising a solid dispersion of Ivacaftor or pharmaceutically acceptable salt thereof and method of manufacturing.
The main object of the present invention is to provide a pharmaceutical composition comprising Ivacaftor having excellent high bioavailability, high solubility which is obtained by using effective and reproducible manufacturing method. The term “Ivacaftor” as used herein refers to Ivacaftor in the form of free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or in amorphous form or mixture thereof.
Ivacaftor is practically insoluble in water and it shows poor bioavailability after oral administration.
In this invention, the pharmaceutical composition comprises a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers and wherein the solid dispersion is prepared by hot-melt extrusion.
The pharmaceutical composition contains a solid dispersion comprising Ivacaftor. The active ingredient is dispersed in a matrix containing polymers, wherein the solid dispersion is prepared by hot-melt extrusion. The expression “solid dispersion” as used herein relates to an active ingredient moleculary dissolved in the solid excipient matrix (solid solution).
Hot-melt extrusion is a manufacturing process where polymeric materials are heated above their glass-transition temperature and mixed with active ingredient, in order to disperse the active ingredient molecularly into the polymer.
According to the one embodiment of the present invention, heating temperatures are used at zones during the hot melt extrusion. The temperature is chosen according to the properties of the polymers and Ivacaftor.
Table 1 : The temperatures of the zones during the hot melt extrusion
Figure imgf000004_0001
It was surprisingly found that pharmaceutical composition of high bioavailability, high solubility and showing improved dissolution rate could be obtained that the presence of at least two polymers in a solid dispersion of Ivacaftor wherein obtained by hot-melt extrusion.
In one embodiment, the amount of Ivacaftor is between 15.0% and 55.0%, preferably between 25.0% and 40.0% by weight of the total composition Suitable polymers are selected from a group comprising hydroxypropyl methyl cellulose acetate succinate, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, homopolymers and copolymers of polyalkylene oxides, polyethylene glycol and polypropylene glycol, homopolymers and copolymers of N-vinyl lactams, N-vinylpyrrolidone, polyvinylpyrrolidone (PVP), Polyvinylpyrrolidone/vinylacetate (PVP/VA), N-vinylcaprolactam, homopolymers and copolymers of acrylic acid and its derivatives, homopolymers and copolymers of methacrylic acid and its derivatives, methylmethacrylate, methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose, starch derivatives or mixtures thereof.
To overcome the solubility of Ivacaftor, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol was selected as one of the polymers in the hot melt extrusion. It is used to enhance the solubility of poorly water-soluble active ingredients by solid dispersion. The glass transition temperature for graft copolymer of polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol (Soluplus®) is 70 °C: this low glass transition temperature makes (Soluplus®) a good candidate for active ingredients.
In one embodiment, the polymers are graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus®) and hydroxypropyl methyl cellulose acetate succinate (HPMCAS).
According to this embodiment, the ratio of weight of hydroxypropyl methyl cellulose acetate succinate to the graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol is in the range of between 0.30 and 0.60, preferably 0.38 and 0.50. This ratio provides an improved solubility and dissolution profile; thus its bioequivalence is high.
In one embodiment, the pharmaceutical composition comprises at least one pharmaceutically excipient selected from fillers, disintegrants, lubricants, glidants, binders or mixtures thereof.
Suitable fillers are selected from the group comprising lactose, lactose monohydrate, spray- dried lactose monohydrate, anhydrous lactose, microcrystalline cellulose, pregelatinized starch, mannitol, corn starch, maltodextrin, dextrin, dextrose, erytritol, fructose, maltose, sucrose, xylitol, dicalcium phosphate, hydroxypropyl betadex, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, ethylcellulose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sugar sphericals, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80 or mixtures thereof.
According to one embodiment of the present invention, a preferred filler to be used is microcrystalline cellulose or lactose or mixtures thereof.
According to one embodiment of this invention, the total amount of filler is between 30.0% and 90%, between 55.0% and 70.0 by weight of the total composition.
Suitable binders are selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, microcrystalline cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyvinyl alcohol, pregelatinized starch, glucose, natural gums, sucrose, sodium alginate, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
Suitable disintegrants are selected from the group comprising calcium carboxymethyl cellulose, crospovidone, cross-linked carboxymethyl cellulose sodium (croscarmellose sodium), starch, sodium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacryline potassium, sodium alginate, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate or mixtures thereof.
In one preferred embodiment, the disintegrant is cross-linked carboxymethyl cellulose sodium (croscarmellose sodium).
According to one embodiment, the disintegrant has an amount of at most %5 by weight of the total composition.
Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, paraffin and mixtures thereof. In one embodiment, the lubricant can be magnesium stearate.
According to one embodiment, the amount of lubricant is between 0.10% and 5.00%, preferably between 0.25% and 2.50%, more preferably between 0.50% and 1 .50% by weight of the total composition.
A preferred surfactant to be used according to the present invention is sodium lauryl sulfate, polysorbate 80, poloxamer, most preferably sodium lauryl sulfate.
According to one embodiment of the present invention, the surfactant is sodium lauryl sulfate.
According to one embodiment, the amount of total surfactant is between 0.05% and 1.50%, preferably between 0.10% and 1 .00% by weight of the total composition.
Suitable glidants are selected from a group comprising colloidal silicon dioxide, talc, aluminum silicate or mixtures thereof.
In one preferred embodiment, the glidant is colloidal silicon dioxide.
According to this embodiment, the amount of glidant is between 0.10% and 5.00%, preferably between 0.25% and 2.50%, more preferably between 0.50% and 1 .50% by weight of the total composition.
In one preferred embodiment, the pharmaceutical composition comprises Ivacaftor as a active agent, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus®) and hydroxypropyl methyl cellulose acetate succinate (HPMCAS) as polymers, croscarmellose sodium as disintegrant, sodium lauryl sulfate as surfactant, colloidal silicon dioxide as glidant, magnesium stearate as lubricant.
According to this preferred embodiment, the composition comprises, a) 15.0-55.0% by weight Ivacaftor b) 0.50-5.00% by weight HPMCAS c) 3.00-9.00% by weight are graft copolymer of polyvinyl caprolactam, polyvinyl acetate, polyethylene glycol (Soluplus®) d) 1 .00-5.00% by weight croscarmellose sodium e) 20.0-40.0% by weight microcrsytalline cellulose f) 20.0-50.0% by weight lactose g) 0.10-5.00% by weight colloidal silicon dioxide h) 0.05-1 .50% by weight sodium lauryl sulfate i) 0.10-5.00% by weight magnesium stearate
The pharmaceutical composition of the invention can be processed into a tablet, capsule form, granules, powders, pellet or unit dose packets.
In one embodiment, the pharmaceutical composition is especially in the tablet form.
According to another embodiment of the present invention, a process for preparing a composition comprising a solid dispersion of Ivacaftor is prepared by hot-melt extrusion: of Extrudate: a) Mixing Ivacaftor, graft copolymer of polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol (Soluplus®), HPMCAS and sodium lauryl sulfate b) Melting this mixture in a hot melt extruder for molecular dispersion of Ivacaftor in the polymer to form extrude of Tablet c) Pulverising and sieving the extrudate d) Mixing the extrudate powder, croscarmellose sodium, sodium lauryl sulfate, lactose e) Sieving colloidal silicon dioxide, microcrystalline cellulose and adding to the mixture f) Adding magnesium stearate to the mixture and mixing g) Compressing the mixture into tablets
Example 1 :
Figure imgf000009_0001
Soluplus: graft copolymer of polyvinyl caprolactam, -polyvinyl acetate, -polyethylene glycol

Claims

CLAIMS A pharmaceutical composition comprising a solid dispersion of Ivacaftor wherein the Ivacaftor is dispersed in a matrix containing at least two polymers and wherein the solid dispersion is prepared by hot-melt extrusion. The pharmaceutical composition according to claim 1 , wherein the amount of Ivacaftor is between 15.0% and 55.0, preferably between 25.0% and 40.0% by weight of the total composition. The pharmaceutical composition according to claim 1 , wherein said at least two polymers are selected from a group comprising hydroxypropyl methyl cellulose acetate succinate, graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, homopolymers and copolymers of polyalkylene oxides, polyethylene glycol and polypropylene glycol, homopolymers and copolymers of N-vinyl lactams,
Nvinylpyrrolidone, polyvinylpyrrolidone, N-vinylcaprolactam, homopolymers and copolymers of acrylic acid and its derivatives, homopolymers and copolymers of methacrylic acid and its derivatives, methylmethacrylate, methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, starch derivatives or mixtures thereof. The pharmaceutical composition according to claim 3, wherein the polymers are hydroxypropyl methyl cellulose acetate succinate and graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol. The pharmaceutical composition according to claim 4, wherein the weight ratio of hydroxypropyl methyl cellulose acetate succinate to the graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol is in the range of between 0.35 and 0.60, preferably 0.40 and 0.50. The pharmaceutical composition according to claim 1 , wherein the composition further comprising at least one pharmaceutically excipient selected from fillers, disintegrants, lubricants, glidants, binders or mixtures thereof. The pharmaceutical composition according to claim 6, wherein filler is selected from a group of comprising lactose, lactose monohydrate, spray-dried lactose monohydrate, anhydrous lactose, microcrystalline cellulose, pregelatinized starch, mannitol, corn starch, maltodextrin, dextrin, dextrose, erytritol, fructose, maltose, sucrose, xylitol, dicalcium phosphate, hydroxypropyl betadex, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, ethylcellulose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sugar sphericals, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80 or mixtures thereof.
8. The pharmaceutical composition according to claim 6, wherein the fillers are microcrystalline cellulose or lactose or mixture thereof.
9. The pharmaceutical composition according to any of the preceding claims, wherein the composition comprises, a) 15.0-55.0% by weight Ivacaftor b) 0.50-5.00 % by weight HPMCAS c) 3.00-9.00% by weight are graft copolymer of polyvinyl caprolactam, -polyvinyl acetatepolyethylene glycol d) 1 .00-5.00% by weight croscarmellose sodium e) 20.0-40.0% by weight microcrsytalline cellulose f) 20.0-50.0% by weight lactose g) 0.10-5.00% by weight colloidal silicon dioxide h) 0.05-1 .50% by weight sodium lauryl sulfate i) 0.10-5.00% by weight magnesium stearate
10. A hot melt extrusion process for preparing the pharmaceutical composition according to claim 9, comprising the following steps; a) Mixing Ivacaftor, graft copolymer of polyvinyl caprolactam, polyvinyl acetate, polyethylene glycol (Soluplus), HPMCAS and sodium lauryl sulfate b) Melting this mixture in a hot melt extruder for molecular dispersion of Ivacaftor in the polymer to form extrude c) Pulverising and sieving the extrudate d) Mixing the extrudate powder, croscarmellose sodium, sodium lauryl sulfate, lactose e) Sieving colloidal silicon dioxide, microcrystalline cellulose and adding to the mixture f) Adding magnesium stearate to the mixture and mixing g) Compressing the mixture into tablets.
11 . The pharmaceutical composition according to any preceding claims, for use in the treatment of cystic fibrosis.
PCT/TR2023/050789 2022-08-17 2023-08-08 Pharmaceutical compositions comprising ivacaftor WO2024039333A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022012995 2022-08-17
TR2022/012995 TR2022012995A1 (en) 2022-08-17 PHARMACEUTICAL COMPOSITIONS COMPRISING IVACAFTOR

Publications (1)

Publication Number Publication Date
WO2024039333A1 true WO2024039333A1 (en) 2024-02-22

Family

ID=89942150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050789 WO2024039333A1 (en) 2022-08-17 2023-08-08 Pharmaceutical compositions comprising ivacaftor

Country Status (1)

Country Link
WO (1) WO2024039333A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US20170326129A1 (en) * 2016-04-25 2017-11-16 Druggability Technologies Ip Holdco Limited Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2022013360A1 (en) * 2020-07-17 2022-01-20 Synthon B.V. Pharmaceutical composition comprising ivacaftor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US20170326129A1 (en) * 2016-04-25 2017-11-16 Druggability Technologies Ip Holdco Limited Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2022013360A1 (en) * 2020-07-17 2022-01-20 Synthon B.V. Pharmaceutical composition comprising ivacaftor

Similar Documents

Publication Publication Date Title
US20190008758A1 (en) Lacosamide controlled release formulation
JP5546860B2 (en) Method for producing a solid dispersion of a highly crystalline therapeutic compound
US6322816B1 (en) Fast-acting analgesic
US10149818B2 (en) Daily formulation of lacosamide
US20110092515A1 (en) Melt granulation process
MX2007014067A (en) Pharmaceutical compositions comprising imatinib and a release retardant.
EP1814528A2 (en) Process for making a highly compressible controlled delivery compositions of metformin
US20200330433A1 (en) Extended release pharmaceutical composition of apremilast
CA3151137A1 (en) Dosage forms for tyk2 inhibitors
WO2008062470A2 (en) Stabilized controlled release dosage form of gliclazide
CA2339193C (en) Pharmaceutical compositions comprising ibuprofen and domperidone
EP3110406B1 (en) Pharmaceutical composition
WO2006123213A1 (en) Modified release formulations of gliclazide
WO2024039333A1 (en) Pharmaceutical compositions comprising ivacaftor
AU2017209981A1 (en) Process of preparing active pharmaceutical ingredient salts
EP4335434A1 (en) Pharmaceutical compositions comprising ivacaftor
EP1732518A1 (en) Clarithromycin extended release formulation
WO2003011256A1 (en) Oral controlled release pharmaceutical composition of a prokinetic agent
TR2022012995A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING IVACAFTOR
US20190142756A1 (en) Drug formulations
WO2013095317A2 (en) Pharmaceutical formulations of flurbiprofen and glucosamin
JPWO2013147135A1 (en) Controlled release pharmaceutical composition
US20170273923A1 (en) Method of administering divalproex
WO2022146344A1 (en) Pharmaceutical compositions comprising alogliptin
CN117482055A (en) Preparation method of low-dose dronedarone hydrochloride tablet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855244

Country of ref document: EP

Kind code of ref document: A1